Painful Diabetic Peripheral Neuropathy of the Feet: Integrating Prescription-Strength Capsaicin into Office Procedures

References

• Colloca L , LudmanT , BouhassiraDet al. Neuropathic pain. Nat. Rev. Dis. Primers.3(16), 17002 (2017).
   PubMedGoogle Scholar
• Jaggi AS , SinghN. Role of different brain areas in peripheral nerve injury-induced neuropathic pain. Brain Res.1381, 187–201 (2011).
   PubMed Web of Science ®Google Scholar
• Anand P , BleyK. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br. J. Anaesth.107(4), 490–502 (2011).
   PubMed Web of Science ®Google Scholar
• Tesfaye S , BoultonAJ , DyckPJet al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care33(10), 2285–2293 (2010).
   PubMed Web of Science ®Google Scholar
• Vincent AM , CalabekB , RobertsL , FeldmanEL. Biology of diabetic neuropathy. Handb. Clin. Neurol.115, 591–606 (2013).
   PubMedGoogle Scholar
• Tesfaye S , BoultonAJ , DickensonAH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care36(9), 2456–2465 (2013).
   PubMed Web of Science ®Google Scholar
• Iqbal Z , AzmiS , YadavRet al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin. Ther.40(6), 828–849 (2018).
   PubMed Web of Science ®Google Scholar
• Sloan G , ShilloP , SelvarajahDet al. A new look at painful diabetic neuropathy. Diabetes Res. Clin. Pract.144, 177–191 (2018).
   PubMed Web of Science ®Google Scholar
• Javed S , AlamU , MalikRA. Treating diabetic neuropathy: present strategies and emerging solutions. Rev. Diabet. Stud.12(1–2), 63–83 (2015).
   PubMedGoogle Scholar
• Gore M , BrandenburgNA , HoffmanDL , TaiKS , StaceyB. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J. Pain7(12), 892–900 (2006).
   PubMed Web of Science ®Google Scholar
• Gore M , BrandenburgNA , DukesE , HoffmanDL , TaiKS , StaceyB. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J. Pain Symptom Manage.30(4), 374–385 (2005).
   PubMed Web of Science ®Google Scholar
• Davies M , BrophyS , WilliamsR , TaylorA. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care29(7), 1518–1522 (2006).
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas (10th Edition). International Diabetes Federation, Brussels, Belgium (2021). https://diabetesatlas.org/
   Google Scholar
• Mick G , BaronR , Correa-IllanesGet al. Is an easy and reliable diagnosis of localized neuropathic pain (LNP) possible in general practice? Development of a screening tool based on IASP criteria. Curr. Med. Res. Opin.30(7), 1357–1366 (2014).
   PubMed Web of Science ®Google Scholar
• St Onge EL , MillerSA. Pain associated with diabetic peripheral neuropathy: a review of available treatments. P. T.33(3), 166–176 (2008).
   PubMedGoogle Scholar
• Saydah SH . Medication use and self-care practices in persons with diabetes. In: Diabetes in America.CowieCC, CasagrandeSS, MenkeA ( Eds). National Institute of Diabetes and Digestive and Kidney Diseases (US), MD, USA (2018).
   Google Scholar
• Dechanont S , MaphantaS , ButthumB , KongkaewC. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf.23(5), 489–497 (2014).
   PubMed Web of Science ®Google Scholar
• Aparasu R , BaerR , AparasuA. Clinically important potential drug-drug interactions in outpatient settings. Res. Social. Adm. Pharm.3(4), 426–437 (2007).
   PubMedGoogle Scholar
• Cascorbi I . Drug interactions--principles, examples and clinical consequences. Dtsch. Arztebl. Int.109(33–34), 546–555 (2012).
   PubMed Web of Science ®Google Scholar
• Qutenza^® (capsaicin) topical system: US prescribing information. Averitas Pharma, Inc, NJ, USA (2022).
   Google Scholar
• Baranidharan G , DasS , BhaskarA. A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain. Ther. Adv. Neurol. Disord.6(5), 287–297 (2013).
   PubMed Web of Science ®Google Scholar
• Leppert W , Malec-MilewskaM , ZajaczkowskaR , WordliseckZ. Transdermal and topical drug administration in the treatment of pain. Molecules23(3), 681 (2018).
   PubMed Web of Science ®Google Scholar
• Frias B , MerighiA. Capsaicin, nociception and pain. Molecules21(6), 797 (2016).
   PubMed Web of Science ®Google Scholar
• Moran MM , SzallasiA. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. Br. J. Pharmacol.175(12), 2185–2203 (2018).
   PubMed Web of Science ®Google Scholar
• Zilliox LA . Neuropathic pain. Continuum (Minneap Minn).23(2, Selected Topics in Outpatient Neurology), 512–532 (2017).
   PubMedGoogle Scholar
• Derry S , MooreRA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev.12(9), CD010111 (2012).
   PubMedGoogle Scholar
• Blonde L , UmpierrezGE , ReddySSet al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocr. Pract.28(10), 923–1049 (2022).
   PubMed Web of Science ®Google Scholar
• Pop-Busli R , AngL , BoultonAJMet al. Diagnosis and treatment of painful diabetic peripheral neuropathy. American Diabetes Association, Inc, VA, USA (2022).
   Google Scholar
• Pickering G , MartinE , TiberghienF , DelormeC. Localized neuropathic pain: an expert consensus on local treatments. Drug Des. Devel. Ther.11, 2709–2718 (2017).
   PubMed Web of Science ®Google Scholar
• Finnerup NB , AttalN , HaroutounianS , McNicolE. Pharmacotherapy for neuropathic pain in adults: a systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol.14(2), 162–173 (2015).
   PubMed Web of Science ®Google Scholar
• Cruccu G , TruiniA. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther.6, 35–42 (2017).
   PubMed Web of Science ®Google Scholar
• Price R , SmithD , FranklinGet al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: Report of the AAN Guideline Subcommittee. Neurology98(1), 31–43 (2022).
   PubMed Web of Science ®Google Scholar
• Stillman M . Clinical approach to patients with neuropathic pain. Cleve. Clin. J. Med.73(8), 726–739 (2006).
   PubMed Web of Science ®Google Scholar
• Qutenza^® (capsaicin) topical system: US prescribing information. Averitas Pharma, Inc, NJ, USA (2022).
   Google Scholar
• Benítez-Angeles M , Morales-LázaroSL , Juárez-GonzálezE , RosenbaumT. TRPV1: Structure, Endogenous Agonists, and Mechanisms. Int. J. Mol. Sci.21(10), 3421 (2020).
   PubMed Web of Science ®Google Scholar
• Lo Vecchio S , AndersenHH , Arendt-NielsenL. The time course of brief and prolonged topical 8% capsaicin-induced desensitization in healthy volunteers evaluated by quantitative sensory testing and vasomotor imaging. Exp. Brain Res.236(8), 2231–2244 (2018).
   PubMed Web of Science ®Google Scholar
• Malmberg AB , MizisinAP , CalcuttNA , von SteinT , RobbinsWR , BleyKR. Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain111(3), 360–367 (2004).
   PubMed Web of Science ®Google Scholar
• Nolano M , SimoneDA , Wendelschafer-CrabbG , JohnsonT , HazenE , KennedyWR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain81(1–2), 135–145 (1999).
   PubMed Web of Science ®Google Scholar
• Kennedy WR , VanhoveGF , LuSP , TobiasJ. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J. Pain.11(6), 579–587 (2010).
   PubMed Web of Science ®Google Scholar
• Noto C , PappagalloM , SzallasiA. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Curr. Opin. Investig. Drugs.10(7), 702–710 (2009).
   PubMedGoogle Scholar
• Premkumar LS , SikandP. TRPV1: a target for next generation analgesics. Curr. Neuropharmacol.6(2), 151–163 (2008).
   PubMed Web of Science ®Google Scholar
• Vinik AI , PerrotS , VinikEJet al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol.16(1), 251 (2016).
   PubMed Web of Science ®Google Scholar
• Feldman EL , CallaghanBC , Pop-BusuiRet al. Diabetic neuropathy. Nat. Rev. Dis. Primers5(1), 41 (2019).
   PubMed Web of Science ®Google Scholar
• Yang H , SloanG , YeYet al. New Perspective in Diabetic Neuropathy: from the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front. Endocrinol. (Lausanne).10, 929 (2019).
   PubMed Web of Science ®Google Scholar
• Wohlrab J , NeubertRH , HeskampML , MichaelJ. Cutaneous drug delivery of capsaicin after in vitro administration of the 8% capsaicin dermal patch system. Skin Pharmacol. Physiol.28(2), 65–74 (2015).
   PubMed Web of Science ®Google Scholar
• Babbar S , MarierJF , MouksassiMSet al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther. Drug Monit.31(4), 502–510 (2009).
   PubMed Web of Science ®Google Scholar
• Blair HA . Capsaicin 8% dermal patch: a review in peripheral neuropathic pain. Drugs78(14), 1489–1500 (2018).
   PubMed Web of Science ®Google Scholar
• Chanda S , BashirM , BabbarS , KogantiA , BleyK. In vitro hepatic and skin metabolism of capsaicin. Drug Metab. Dispos.36(4), 670–675 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson DM , Robinson-PappJ , VanJet al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J. Pain18(1), 42–53 (2017).
   PubMed Web of Science ®Google Scholar
• Vinik AI , PerrotS , VinikEJet al. Repeat treatment with capsaicin 8% patch (179 mg capsaicin cutaneous patch): effects on pain, quality of life, and patient satisfaction in painful diabetic peripheral neuropathy: an open-label, randomized controlled clinical trial. J. Curr. Med. Res. Opin.2(12), 388–401 (2019).
   Google Scholar
• Freynhagen R , ArgoffC , EerdekensM , EngelenS , PerrotS. Progressive response to repeat application of capsaicin 179 mg (8% w/w) cutaneous patch in peripheral neuropathic pain: comprehensive new analysis and clinical implications. Pain Med.22(10), 2324–2336 (2021).
   PubMed Web of Science ®Google Scholar
• van Nooten F , TreurM , PantiriK , StokerM , CharokopouM. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin. Ther.39(4), 787–803.e18 (2017).
   PubMed Web of Science ®Google Scholar
• Peppin JF , MajorsK , WebsterLR , SimpsonDM. Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J. Pain Res.4, 385–392 (2011).
   PubMedGoogle Scholar
• Wagner T , Roth-DaniekA , SellA , EnglandJ , KernK-U. Capsaicin 8% patch for peripheral neuropathic pain: review of treatment best practice from ‘real-world’ clinical experience. Pain Manag.2(3), 239–250 (2012).
   PubMedGoogle Scholar